Clinical TrialApr 17, 2026, 03:12 PM
Evaxion EVX-01 Phase 2 Data: 86% Immune Response Rate
AI Summary
Evaxion A/S announced new Phase 2 data for its personalized cancer vaccine EVX-01, demonstrating an 86% success rate in vaccine targets triggering a tumor-specific immune response. This high rate, significantly above other reported methods, validates Evaxion's AI-Immunology™ platform. The data also showed durable two-year vaccine-specific immune responses and a positive correlation between AI-prediction scores and immune response magnitude, reinforcing the platform's predictive power and the vaccine's potential for strong anti-tumor effects.
Key Highlights
- EVX-01 Phase 2 data shows 86% of vaccine targets trigger tumor-specific immune response.
- New data includes two-year analysis showing durable vaccine-specific immune responses.
- Positive correlation between AI-prediction scores and magnitude of immune responses.
- Trial investigates EVX-01 with KEYTRUDA® in advanced melanoma patients.
- Previous data showed a 75% Objective Response Rate.